The company's medical supply business should continue to benefit from the rapid drop in new covid cases in Japan, while its total pack produce business will be a key beneficiary of the capex cycle.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.